Moxonidine for Hypertension in Metabolic Syndrome
The centrally acting antihypertensive, moxonidine, reduces blood pressure (BP) in mild-to-moderate hypertensive patients as effectively as most first-line antihypertensives when used as monotherapy, and also in combination with other antihypertensive agents. It improves the metabolic profile in patients with hypertension and diabetes mellitus or impaired glucose tolerance, is well tolerated, has a low potential for drug interactions and may be administered once daily in most patients.
Modern Medicine – Issue 3 2021
